KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CRISPR Therapeutics AG (CRSP) Gross Profit: 2015-2024

Historic Gross Profit for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Dec 2024 value amounting to $37.3 million.

  • CRISPR Therapeutics AG's Gross Profit rose 47.67% to $889,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $38.3 million, marking a year-over-year decrease of 81.10%. This contributed to the annual value of $37.3 million for FY2024, which is 89.95% down from last year.
  • Per CRISPR Therapeutics AG's latest filing, its Gross Profit stood at $37.3 million for FY2024, which was down 89.95% from $371.2 million recorded in FY2023.
  • CRISPR Therapeutics AG's Gross Profit's 5-year high stood at $915.0 million during FY2021, with a 5-year trough of $719,000 in FY2020.
  • Over the past 3 years, CRISPR Therapeutics AG's median Gross Profit value was $37.3 million (recorded in 2024), while the average stood at $136.6 million.
  • In the last 5 years, CRISPR Therapeutics AG's Gross Profit spiked by 127,154.94% in 2021 and then crashed by 99.87% in 2022.
  • Yearly analysis of 5 years shows CRISPR Therapeutics AG's Gross Profit stood at $719,000 in 2020, then surged by 127,154.94% to $915.0 million in 2021, then tumbled by 99.87% to $1.2 million in 2022, then soared by 30,885.48% to $371.2 million in 2023, then crashed by 89.95% to $37.3 million in 2024.